Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Etoposide + Nutlin-3a|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Etoposide||Vepesid||EPEG|Eposin|VP-16|VP-16-213||TOPO2 inhibitor 5||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Nutlin-3a||Nutlin|Nutlin-3||MDM2 Inhibitor 20||Nutlin-3a is an MDM2 inhibitor which activates p53 and results in cancer cells undergoing apoptosis and cellular senescence. Nutlin-3 is a candidate for neoadjuvant therapy in cancers with a functional p53 (PMID: 18451145, PMID: 32653500).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 del||ovarian cancer||sensitive||Etoposide + Nutlin-3a||Preclinical||Actionable||In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101).||25964101|
|TP53 mutant||ovarian cancer||sensitive||Etoposide + Nutlin-3a||Preclinical||Actionable||In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis in ovarian cancer cell lines with TP53 inactivating mutations in culture (PMID: 25964101).||25964101|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|